Sagimet Biosciences Inc. financial data

Symbol
SGMT on Nasdaq
Location
155 Bovet Rd., Suite 303, San Mateo, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Return On Equity -39.9 % -91.6%
Return On Assets -38.4 % -91.4%

Shares

Label TTM Value / Value Unit Change %
Weighted Average Number of Shares Outstanding, Basic 32.2M shares +0.88%
Weighted Average Number of Shares Outstanding, Diluted 32.2M shares +0.88%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 49.5M USD +123%
General and Administrative Expense 17.4M USD +8.34%
Operating Income (Loss) -66.9M USD -84.4%
Net Income (Loss) Attributable to Parent -59.4M USD -103%
Earnings Per Share, Basic -1 USD/shares -103%
Earnings Per Share, Diluted -1 USD/shares -103%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 42.3M USD -55.9%
Marketable Securities, Current 83.1M USD +18%
Cash, Cash Equivalents, and Short-term Investments 136M USD -28.1%
Other Assets, Current 173K USD +33.1%
Assets, Current 127M USD -23.7%
Operating Lease, Right-of-Use Asset 152K USD +0.66%
Assets 137M USD -27.3%
Accounts Payable, Current 1.92M USD -3.66%
Employee-related Liabilities, Current 865K USD +31.7%
Accrued Liabilities, Current 5.17M USD +44.5%
Liabilities, Current 7.25M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 76K USD
Retained Earnings (Accumulated Deficit) -324M USD -22.5%
Stockholders' Equity Attributable to Parent 130M USD -29%
Liabilities and Equity 137M USD -27.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 42.3M USD -55.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -59.3M USD -103%
Operating Lease, Liability, Current 152K USD -0.65%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 454M USD +1.37%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 6.15M USD +14.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%